ActivePhase 4ACTRN12605000162617

A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis

A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin to determine the effect of dose on disease parameters in cystic fibrosis


Sponsor

Associate Professor Joseph McCormack, University of Queensland, Department of Medicine, Mater Hospital, South Brisbane, 4101

Enrollment

184 participants

Start Date

May 21, 2002

Study Type

Interventional

Conditions


Eligibility

Sex: Both males and femalesMin Age: 6 Yearss

Plain Language Summary

Simplified for easier understanding

This clinical trial involves an A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. You may be eligible if you are aged 6 or older. Participation may involve medical assessments, follow-up visits, and possibly receiving a study treatment or placebo.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

A 6-month randomised double-blind trial of 250mg daily versus 1200mg weekly azithromycin in cystic fibrosis

A 6-month randomised double-blind trial of 250mg daily versus 1200mg weekly azithromycin in cystic fibrosis


Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12605000162617


Related Trials